Comparing Myo-Inositol and Folic Acid with and without D-Chiro-Inositol for The Management of Polycystic Ovary Syndrome

Reja Akram; Saghir Ahmed Jafri; Shahida  Malik; Sameena  Nisar; Amna  Irum

doi:10.36283/ziun-pjmd13-4/011

Authors

Reja Akram Nur International University, Lahore
Saghir Ahmed Jafri Nur International University, Lahore
Shahida Malik Kiran International Hospital, Sialkot
Sameena Nisar Sameena Nisar Hospital, Sialkot
Amna Irum Nur International University, Lahore

DOI:

https://doi.org/10.36283/ziun-pjmd13-4/011

Keywords:

Myo-Inositol, D-Chiro Inositol, Folic Acid, Testosterone

Abstract

Background: Polycystic ovarian syndrome (PCOS) is an endocrinological disease of women of the reproductive age group. The study aimed to compare the efficacy of Myo-inositol and folic acid with and without D-chiro-inositol in the improvement of symptoms of PCOS within 4 months for the evaluation of the most effective therapeutic regimen.

Methods: This Quasi-experimental study was conducted at Gynecology & Obstetrics OPD of two Private Healthcare Hospitals in Sialkot from February 2024-June 2024. The Rotterdam criteria (2003) was used for diagnosis of PCOS in non-pregnant women aged between 18-35 years. A total of 90 PCOS patients (45 in each group) were enrolled using a purposive sampling technique and distributed into two treatment groups. Group A received MI 2000 mg + DCI 50 mg + FA 200 mcg while Group B received MI 2000 mg + FA 200 mcg BD, after meal, for 17-18 weeks. Patients’ menstrual cycle history, BMI, transabdominal-ultrasonographic picture, and serum total testosterone levels were evaluated at Day 0, 60, and 120 to compare these measurements before and after initiation of treatment. SPSS was used to analyze the data. Independent samples t-test and Repeated measures ANOVA were used to analyze the data. P-value ≤ 0.05 was considered statistically significant.

Results: After the intervention, body mass index (kg/m²), serum total testosterone levels (ng/dl), and follicular number per ovary decreased, with Group A demonstrating better performance with p-values 0.03, 0.04, and < 0.001 respectively. Both groups exhibited increased follicular size in both ovaries and decreased ovarian volumes. By Day 120, menstrual cycle regularity was more pronounced in Group A than in Group B (1.00 ± 0.00 and 1.13 ± 0.34 respectively, p-value <0.001.

Conclusion: Myo-inositol + D-chiro Inositol + Folic acid and Myo-Inositol + Folic acid showed a change in the studied variables, however, Myo-inositol + D-chiro Inositol + Folic acid demonstrated more efficacy in alleviating PCOS symptoms compared to Myo-Inositol + Folic acid.

Author Biographies

Reja Akram, Nur International University, Lahore

Department of Physiology, MPhil Student
Saghir Ahmed Jafri, Nur International University, Lahore

Professor and Dean Basic Sciences/Academics
Shahida Malik , Kiran International Hospital, Sialkot

Asst. Prof. Obstetrician & Gynecologist
Sameena Nisar , Sameena Nisar Hospital, Sialkot

Consultant Obstetrician & Gynecologist,
Amna Irum , Nur International University, Lahore

Asst. Prof. Physiology, Department of Physiology

References

Nazish Gul, Najma Bibi, Maria Ghafoor, Rubina Babar, Fauzia Anbreen. Frequency of Polycystic Ovary Disease in Adolescent. Pakistan Journal of Medical & Health Sciences. 2023 Mar. 31;17(02):512. doi: https://doi.org/10.53350/pjmhs2023172512. Available from: https://pjmhsonline.com/index.php/pjmhs/article/view/4368

Christ JP, Cedars MI. Current Guidelines for Diagnosing PCOS. Diagnostics (Basel). 2023 Mar 15;13(6):1113. doi: 10.3390/diagnostics13061113. PMID: 36980421; PMCID: PMC10047373

Khan S, Rehman S, Chughani G, Rehman M, Majid E, Amir F, Bano K. Association of Polycystic Ovarian Syndrome with Metabolic Disorders. J. Bahria Univ. Med. Dent. Coll. 2022 Dec. 30;13(01):03-7. doi: 10.51985/JBUMDC202221. Available from: https://jbumdc.bahria.edu.pk/index.php/ojs/article/view/1057

Livadas S, Anagnostis P, Bosdou JK, Bantouna D, Paparodis R. Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. World J Diabetes. 2022 Jan 15;13(1):5-26. doi: 10.4239/wjd.v13.i1.5. PMID: 35070056; PMCID: PMC8771268.

Tahir FN, Kanwal S, Safdar M, Malik AA, Hakim S, Ashraf MN. Polycystic Ovaries and Associated Clinical and Biochemical Features in Young Women. Pakistan Journal of Medical and Health Sciences 2023 May 22;17(3):693–696. doi: 10.53350/pjmhs2023173693.

Ikram-u-Allah, Sabeen N, Javed Iqbal Q, Zulfiqar S, Wasim T. Myoinositol In Restoring Spontaneous Ovarian Activity in Patients with Polycystic Ovarian Syndrome (PCOS). Esculapio - JSIMS. 2023 Jul. 20;16(3):41-5. doi: 10.51273/esc20.2516310. Available from: https://esculapio.pk/journal/index.php/journal-files/article/view/34

Khatoon R, Ali HS, Kulsoom O, Rana MY, Maheshwari M. Impact of Myo-Inositol on Ovary and Menstrual Cycle in Polycystic Ovarian Syndrome (PCOS) – A Therapeutic Approach. Pak J Med Dent. 2022;11(3): 59-65. doi: 10.36283/PJMD11-3/010

Greff D, Juhász AE, Váncsa S, Váradi A, Sipos Z, Szinte J, Park S, Hegyi P, Nyirády P, Ács N, Várbíró S, Horváth EM. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023 Jan 26;21(1):10. doi: 10.1186/s12958-023-01055-z. PMID: 36703143; PMCID: PMC9878965.

Wojciechowska A, Osowski A, Jóźwik M, Górecki R, Rynkiewicz A, Wojtkiewicz J. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS. Int J Mol Sci. 2019 Nov 18;20(22):5787. doi: 10.3390/ijms20225787. PMID: 31752081; PMCID: PMC6888190.

Campbell S, Greenwood M, Prior S, Shearer T, Walkem K, Young S, Bywaters D, Walker K. Purposive sampling: complex or simple? Research case examples. J Res Nurs. 2020 Dec;25(8):652-661. doi: 10.1177/1744987120927206. Epub 2020 Jun 18. PMID: 34394687; PMCID: PMC7932468.

Gambioli R, Forte G, Aragona C, Bevilacqua A, Bizzarri M, Unfer V. The use of D-chiro-Inositol in clinical practice. Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):438-446. doi: 10.26355/eurrev_202101_24412. PMID: 33506934.

Merviel P, James P, Bouée S, Le Guillou M, Rince C, Nachtergaele C, Kerlan V. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health. 2021 Jan 19;18(1):13. doi: 10.1186/s12978-021-01073-3. PMID: 33468143; PMCID: PMC7816413.

Cussen L, McDonnell T, Bennett G, Thompson CJ, Sherlock M, O'Reilly MW. Approach to androgen excess in women: Clinical and biochemical insights. Clin Endocrinol (Oxf). 2022 Aug;97(2):174-186. doi: 10.1111/cen.14710. Epub 2022 Mar 29. PMID: 35349173; PMCID: PMC9541126.

Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-2469. doi: 10.1210/clinem/dgad463. PMID: 37580314; PMCID: PMC10505534.

Meczekalski B, Niwczyk O, Kostrzak A, Maciejewska-Jeske M, Bala G, Szeliga A. PCOS in Adolescents-Ongoing Riddles in Diagnosis and Treatment. J Clin Med. 2023 Feb 3;12(3):1221. doi: 10.3390/jcm12031221. PMID: 36769869; PMCID: PMC9918268.

Hussein K, Karami M. Association between insulin resistance and abnormal menstrual cycle in Saudi females with polycystic ovary syndrome. Saudi Pharm J. 2023 Jun;31(6):1104-1108. doi: 10.1016/j.jsps.2023.03.021. Epub 2023 Apr 5. PMID: 37293383; PMCID: PMC10244367.

Muhammad LN. Guidelines for repeated measures statistical analysis approaches with basic science research considerations. J Clin Invest. 2023 Jun 1;133(11):e171058. doi: 10.1172/JCI171058. PMID: 37259921; PMCID: PMC10231988.

Alenezi SA, Khan R, Amer S. The Impact of High BMI on Pregnancy Outcomes and Complications in Women with PCOS Undergoing IVF-A Systematic Review and Meta-Analysis. J Clin Med. 2024 Mar 10;13(6):1578. doi: 10.3390/jcm13061578. PMID: 38541804; PMCID: PMC10970739.

Facchinetti F, Bizzarri M, Benvenga S, D'Anna R, Lanzone A, Soulage C, Di Renzo GC, Hod M, Cavalli P, Chiu TT, Kamenov ZA, Bevilacqua A, Carlomagno G, Gerli S, Oliva MM, Devroey P. Results from the International Consensus Conference on Myo-inositol and d-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. Eur J Obstet Gynecol Reprod Biol. 2015 Dec;195:72-76. doi: 10.1016/j.ejogrb.2015.09.024. Epub 2015 Oct 3. PMID: 26479434.

Advani K, Batra M, Tajpuriya S, Gupta R, Saraswat A, Nagar HD, Makwana L, Kshirsagar S, Kaul P, Ghosh AK, Pradhan S, Mehta A, Jaiswal A, Nakhate KT, Kamdi S. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study. J Obstet Gynaecol. 2020 Jan;40(1):96-101. doi: 10.1080/01443615.2019.1604644. Epub 2019 Jul 24. PMID: 31339394.

Colak E, Ozcimen EE, Tohma YA, Ceran MU. May myo-inositol and d-chiro-inositol (40:1) treatment be a good option on normal-weighted polycystic ovary syndrome patients without insulin resistance? J Obstet Gynaecol Res. 2020 Dec;46(12):2605-2611. doi: 10.1111/jog.14505. Epub 2020 Sep 28. PMID: 32989863.

Fedeli V, Unfer V, Dinicola S, Laganà AS, Canipari R, Monti N, Querqui A, Galante E, Laurenzi G, Bizzarri M. Inositol Restores Appropriate Steroidogenesis in PCOS Ovaries Both In Vitro and In Vivo Experimental Mouse Models. Cells. 2024 Jul 9;13(14):1171. doi: 10.3390/cells13141171. PMID: 39056753; PMCID: PMC11275052.

Pustotina O, Myers SH, Unfer V, Rasulova I. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecol Obstet Invest. 2024;89(2):131-139. doi: 10.1159/000536163. Epub 2024 Jan 31. PMID: 38295772; PMCID: PMC11126204.

Zeng LH, Rana S, Hussain L, Asif M, Mehmood MH, Imran I, Younas A, Mahdy A, Al-Joufi FA, Abed SN. Polycystic Ovary Syndrome: A Disorder of Reproductive Age, Its Pathogenesis, and a Discussion on the Emerging Role of Herbal Remedies. Front Pharmacol. 2022 Jul 18;13:874914. doi: 10.3389/fphar.2022.874914. PMID: 35924049; PMCID: PMC9340349.

Monastra G, Unfer V, Harrath AH, Bizzarri M. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol. 2017 Jan;33(1):1-9. doi: 10.1080/09513590.2016.1247797. Epub 2016 Nov 29. PMID: 27898267.

Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5512-5521. doi: 10.26355/eurrev_201906_18223. PMID: 31298405.

Bizzarri M, Monti N, Piombarolo A, Angeloni A, Verna R. Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review. Nutrients. 2023 Apr 13;15(8):1875. doi: 10.3390/nu15081875. PMID: 37111094; PMCID: PMC10145676.

Vyas L, Raiturker AP, Sud S, Goyyal P, Abhyankar M, Revankar S, Walia S. Management of polycystic ovary syndrome among Indian women using myo-inositol and D-chiro-inositol. Bioinformation. 2022 Feb 28;18(2):103-110. doi: 10.6026/97320630018103. PMID: 36420435; PMCID: PMC9649498.

Dietz de Loos A, Jiskoot G, Beerthuizen A, Busschbach J, Laven J. Metabolic health during a randomized controlled lifestyle intervention in women with PCOS. Eur J Endocrinol. 2021 Nov 30;186(1):53-64. doi: 10.1530/EJE-21-0669. PMID: 34714771; PMCID: PMC8679850.